However, PD1 ligands (PD-L1, PD-L2) are expressed on many types of cancer cells, and resulting in the suppression of antitumor immune response.[1] Nivolumab (Opdivo) is a recently developed monoclonal IgG antibody blocking PD1, leading to restoration of the natural T-cell-mediated immune response against the cancer cells. Here, PDCD1LG2 is linked to cancer.